Extended mortality benefit of early postinfarction reperfusion

Circulation

Volumn 97, Issue 16, 1998, Pages 1549-1556

  Ross, Allan M ^a   Coyne, Karin S ^a   Moreyra, Eduardo ^a   Reiner, Jonathan S ^a   Greenhouse, Samuel W ^a   Walker, Pamela L ^a   Simoons, Maarten L ^b   Draoui, Yasmine C ^a   Califf, Robert M ^c   Topol, Eric J ^e   Van de Werf, Frans ^d   Lundergan, Conor F ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NONE

Author keywords

Follow up studies; Mortality; Myocardial infarction; Reperfusion; Thrombolysis

Indexed keywords

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CINEANGIOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032574633     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.16.1549     Document Type: Article

References (20)

1. Chesebro JH, Knatterud G, Robens R, Borer J, Cohen L, Dalen J, Dodge H, Francis C, Hillis D, Ludbrook P, Markis J, Mueller H, Passamani E, Powers E, Rao A, Robertson T, Ross A, Ryan T, Sobel E, Willerson J, Williams D, Zaret B, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;765:142-157.
2. Multicenter Post-Infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:321-336.
3. Gruppo Italiano per lo Studio della Streptochinasi nell'lnfarcto Miocardico. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-874.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
5. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
6. Terrin M, Williams D, Kleiman N, Willerson J, Mueller H, Desvigne-Nickens P, Forman S, Knatterud G, Braunwald E, for the TIMI investigators. Two- and three-year results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial. J Am Coll Cardiol. 1993;22:1763-1772.
7. The GUSTO-I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
8. Califf R, White H, Van de Werf F, Sadowski Z, Armstrong P, Vahanian A, Simoons M, Simes R, Lee K, Topol E, for the GUSTO-I Investigators. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation. 1996;94:1233-1238.
9. The GUSTO-I Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
10. Lee K, Woodlief L, Topol E, Weaver D, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf R, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
11. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
12. ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous Streptokinase in acute myo- cardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986;314:1465-1471.
13. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
14. Wilcox R, von der Lippe G, Olsson C, Jensen G, Skene A, Hampton J, for the ASSET (Ango-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet. 1988;2:525-530.
15. Fibrinolytic Therapy Trialists' (FIT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
16. Simoons ML, Vos J, Tijssen J, Vermeer F, Verheught F, Krauss X, Cats V. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Imeruniversity Cardiology Institute of the Netherlands. J Am Coll Cordiol. 1989;14:1609-1615.
17. Lenderink T, Simoons M, Van Es G, Van de Werf F, Verstraete M, Arnold A, for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 1995;92:1110-1116.
18. GISSI-2, and International Study Group. Six month survival in 20,891 patients with acute myocardial infarction between alteplase and streptokinase with or without heparin. Eur Heart J. 1992;13:1692-1697.
19. ISIS 3. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,229 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
20. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation. 1995;91:2862-2864.